Cargando…

Cholesterol esterification inhibition and gemcitabine synergistically suppress pancreatic ductal adenocarcinoma proliferation

Recent advances have recognized metabolic reprogramming as an underlying mechanism for cancer drug resistance. However, the role of cholesterol metabolism in drug resistance remain elusive. Herein, we report an increased accumulation of cholesteryl ester in gemcitabine-resistant pancreatic ductal ad...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Junjie, Qu, Xiaochao, Tian, Jie, Zhang, Jian-Ting, Cheng, Ji-Xin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2018
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5831104/ https://www.ncbi.nlm.nih.gov/pubmed/29489864 http://dx.doi.org/10.1371/journal.pone.0193318

Ejemplares similares

Abrogating cholesterol esterification suppresses growth and metastasis of pancreatic cancer
por: Li, J, et al.
Publicado: (2016)

Cholesterol esterification and p53-mediated tumor suppression
por: Li, Youjun, et al.
Publicado: (2023)

Metronomic gemcitabine suppresses tumour growth, improves perfusion, and reduces hypoxia in human pancreatic ductal adenocarcinoma
por: Cham, K K Y, et al.
Publicado: (2010)

Suppression of Endothelial Cell FAK Expression Reduces Pancreatic Ductal Adenocarcinoma Metastasis after Gemcitabine Treatment
por: Roy-Luzarraga, Marina, et al.
Publicado: (2022)

Integrated stress response is critical for gemcitabine resistance in pancreatic ductal adenocarcinoma
por: Palam, L R, et al.
Publicado: (2015)

Circular RNA Signature Predicts Gemcitabine Resistance of Pancreatic Ductal Adenocarcinoma
por: Shao, Feng, et al.
Publicado: (2018)

Resistance to Gemcitabine in Pancreatic Ductal Adenocarcinoma: A Physiopathologic and Pharmacologic Review
por: Koltai, Tomas, et al.
Publicado: (2022)

Anti-tumor effect of avadomide in gemcitabine-resistant pancreatic ductal adenocarcinoma
por: Nishi, Hidemi, et al.
Publicado: (2023)

OSI-027 inhibits pancreatic ductal adenocarcinoma cell proliferation and enhances the therapeutic effect of gemcitabine both in vitro and in vivo
por: Zhi, Xiao, et al.
Publicado: (2015)

NUCB1 Suppresses Growth and Shows Additive Effects With Gemcitabine in Pancreatic Ductal Adenocarcinoma via the Unfolded Protein Response
por: Hua, Yong-Qiang, et al.
Publicado: (2021)

Real-world outcomes of adjuvant gemcitabine versus gemcitabine plus capecitabine for resected pancreatic ductal adenocarcinoma
por: Kang, Sora, et al.
Publicado: (2022)

Real‐world evidence of adjuvant gemcitabine plus capecitabine vs gemcitabine monotherapy for pancreatic ductal adenocarcinoma
por: de Jong, Evelien J. M., et al.
Publicado: (2021)

Pancreatic ductal adenocarcinoma cells regulated the gemcitabine‐resistance function of CAFs by LINC00460
por: Zhu, Xiao‐Xu, et al.
Publicado: (2022)

Lipocalin2 Promotes Invasion, Tumorigenicity and Gemcitabine Resistance in Pancreatic Ductal Adenocarcinoma
por: Leung, Lisa, et al.
Publicado: (2012)

Immunobiological effects of gemcitabine and capecitabine combination chemotherapy in advanced pancreatic ductal adenocarcinoma
por: Middleton, Gary, et al.
Publicado: (2016)

Development of gemcitabine-resistant patient-derived xenograft models of pancreatic ductal adenocarcinoma
por: Miller, Aubrey L., et al.
Publicado: (2020)

Modified gemcitabine plus nab‐paclitaxel regimen in advanced pancreatic ductal adenocarcinoma
por: Rogers, Jane E., et al.
Publicado: (2020)

Lauric Acid Overcomes Hypoxia-Induced Gemcitabine Chemoresistance in Pancreatic Ductal Adenocarcinoma
por: Takagi, Tadataka, et al.
Publicado: (2023)

The BET inhibitor I-BET762 inhibits pancreatic ductal adenocarcinoma cell proliferation and enhances the therapeutic effect of gemcitabine
por: Xie, Fang, et al.
Publicado: (2018)

Ubiquitous Aberration in Cholesterol Metabolism across Pancreatic Ductal Adenocarcinoma
por: Gunda, Venugopal, et al.
Publicado: (2022)

Mechanism and Physiologic Significance of the Suppression of Cholesterol Esterification in Human Interstitial Fluid
por: Miller, Norman E., et al.
Publicado: (2016)

MicroRNA-410-3p attenuates gemcitabine resistance in pancreatic ductal adenocarcinoma by inhibiting HMGB1-mediated autophagy
por: Xiong, Junjie, et al.
Publicado: (2017)

The anti-fibrotic effect of GV1001 combined with gemcitabine on treatment of pancreatic ductal adenocarcinoma
por: Park, Joo Kyung, et al.
Publicado: (2016)

Survivin Splice Variant 2β Enhances Pancreatic Ductal Adenocarcinoma Resistance to Gemcitabine
por: Fuller, Ryan N, et al.
Publicado: (2022)

Extracellular Vesicles Inhibit the Response of Pancreatic Ductal Adenocarcinoma Cells to Gemcitabine and TRAIL Treatment
por: Rimmer, Ella, et al.
Publicado: (2022)

dCK Expression and Gene Polymorphism With Gemcitabine Chemosensitivity in Patients With Pancreatic Ductal Adenocarcinoma: A Strobe-Compliant Observational Study
por: Xiong, Junjie, et al.
Publicado: (2016)

Galectin-3 Released by Pancreatic Ductal Adenocarcinoma Suppresses γδ T Cell Proliferation but Not Their Cytotoxicity
por: Gonnermann, Daniel, et al.
Publicado: (2020)

Cholesterol esterification inhibition and imatinib treatment synergistically inhibit growth of BCR-ABL mutation-independent resistant chronic myelogenous leukemia
por: Bandyopadhyay, Shovik, et al.
Publicado: (2017)

Harmine suppresses the proliferation of pancreatic cancer cells and sensitizes pancreatic cancer to gemcitabine treatment
por: Wu, Lin-Wen, et al.
Publicado: (2019)

Interventional Nanotheranostics of Pancreatic Ductal Adenocarcinoma
por: Li, Junjie, et al.
Publicado: (2016)

OXCT1 Enhances Gemcitabine Resistance Through NF-κB Pathway in Pancreatic Ductal Adenocarcinoma
por: Ding, Jinsheng, et al.
Publicado: (2021)

Efficacy and safety of gemcitabine plus S-1 vs. gemcitabine plus nab-paclitaxel in treatment-naïve advanced pancreatic ductal adenocarcinoma
por: Zhu, Zhou, et al.
Publicado: (2023)

MicroRNA-155 Controls Exosome Synthesis and Promotes Gemcitabine Resistance in Pancreatic Ductal Adenocarcinoma
por: Mikamori, Manabu, et al.
Publicado: (2017)

Induction Chemotherapy With FOLFIRINOX Followed by Chemoradiation With Gemcitabine in Patients With Borderline-Resectable Pancreatic Ductal Adenocarcinoma
por: Acuna-Villaorduna, Ana, et al.
Publicado: (2022)

Impact of Sarcopenia on Patients with Localized Pancreatic Ductal Adenocarcinoma Receiving FOLFIRINOX or Gemcitabine as Adjuvant Chemotherapy
por: Mortier, Victor, et al.
Publicado: (2022)

An Inflammatory Response Related Gene Signature Associated with Survival Outcome and Gemcitabine Response in Patients with Pancreatic Ductal Adenocarcinoma
por: Xiao, Zhijun, et al.
Publicado: (2021)

Retraction Note: The BET inhibitor I-BET762 inhibits pancreatic ductal adenocarcinoma cell proliferation and enhances the therapeutic effect of gemcitabine
por: Xie, Fang, et al.
Publicado: (2023)

A Phase I Study of Gemcitabine/Nab-Paclitaxel/S-1 Chemotherapy in Patients With Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma
por: Chang, Chen, et al.
Publicado: (2022)

Up-regulation of HER2 by gemcitabine enhances the antitumor effect of combined gemcitabine and trastuzumab emtansine treatment on pancreatic ductal adenocarcinoma cells
por: Kan, Shin, et al.
Publicado: (2015)

SLPI knockdown induced pancreatic ductal adenocarcinoma cells proliferation and invasion
por: Zhang, Wei, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_2so9bq2s4hjttcbu750prj3eh5